Modulation of CIP2A dimerization and protein stability via druggable pocket

Pavic, K.; Moyano-Gomez, P.; Roivas, P.; Kurkinen, S.; Parkkola, H.; Kauppinen, L.; Rauhamäki, S.; Lehtinen, A.; Rosenqvist, P.; Virta, P.; Pentikäinen, U.; Pentikäinen, O. T.; Westermarck, J.

doi:10.1101/2025.10.13.682046

bioRxiv · 10.1101/2025.10.13.682046

Modulation of CIP2A dimerization and protein stability via druggable pocket

Pavic, K.·Moyano-Gomez, P.·Roivas, P.·Kurkinen, S.·Parkkola, H.·Kauppinen, L.·Rauhamäki, S.·Lehtinen, A.·Rosenqvist, P.·Virta, P.·Pentikäinen, U.·Pentikäinen, O. T.·Westermarck, J.

View original source ↗Export metadata ↓

Abstract

Cancerous inhibitor of PP2A (CIP2A) supports malignant growth across several cancer types. CIP2A is also a synthetic lethal therapy target for BRCA-mutant cancers. In addition, CIP2A causes Alzheime[r]s disease (AD) phenotype in mice. However, it is not dispensable for normal development and growth. Therefore, CIP2A is very lucrative therapy target in cancer and AD. So far it has been unclear whether the CIP2A protein harbors any druggable pockets amenable to targeting by small molecules. Here we discover a druggable pocket adjacent to the homodimerization domain of CIP2A. Mutagenesis demonstrates that pocket impacts CIP2A homodimerization, PP2A interaction, and full-length CIP2A protein stability in cancer cells. Further, we identify Gambogenic acid (GNA) as a tool compound that directly binds to CIP2A pocket region. GNA and its derivative Gambogic acid dissociate CIP2A homodimer in vitro and cause CIP2A destabilization in cellulo. The pocket contributes to the impact of GNA on homodimerization based on the protein fragment and mutagenesis analysis. These results identify structural vulnerability on CIP2A and may facilitate development of targeted CIP2A inhibitors with broad disease applicability.

Explore related subjects

biochemistry Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Pavic, K., Moyano-Gomez, P., Roivas, P., Kurkinen, S., Parkkola, H., Kauppinen, L., Rauhamäki, S., Lehtinen, A., Rosenqvist, P., Virta, P., Pentikäinen, U., Pentikäinen, O. T., Westermarck, J.. 2025-10-14. Modulation of CIP2A dimerization and protein stability via druggable pocket. https://doi.org/10.1101/2025.10.13.682046

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Machine Learning for Toxicity Prediction in Low-Sample Molecular Classes

Deep learning models such as Chemprop have advanced quantitative molecular property prediction, but their reliance on large training sets limits use in data-scarce domains. We propose a framework that fine-tunes a general baseline model trained on publicly available data on small, class-specific datasets. The resulting models retain the baseline's generalization ability while gaining class-specific accuracy and produce probabilistic outputs that capture uncertainty in the training data. We demonstrate the approach on three toxicity classes defined by a common core structure, target, or mode of action: (i) organophosphates, (ii) androgen receptor antagonists, and (iii) estrogen receptor beta antagonists. Each fine-tuned model outperforms classical machine-learning methods and the EPA TEST tool. The probabilistic nature of the predictions enables prioritization of compounds for experimental validation and seamless integration with data streams of varying quality, supporting iterative decision-making in chemical safety and drug discovery.

biochemistry↗

bioRxiv2026

Phosphorylation-dependent binding of the Adenomatous Polyposis Coli protein to β-TrCP1 regulates β-catenin destruction

Wnt signaling controls cellular development by regulating levels of {beta}-catenin, a dual transcription factor and adhesion protein. The tumor suppressor gene Adenomatous Polyposis coli (APC) is a negative regulator of Wnt signaling that acts by interacting with multiple proteins in the destruction complex to drive {beta}-catenin degradation. Mutations in APC cause deregulation of Wnt/{beta}-catenin signaling contributing to the development of several types of cancer, especially colorectal cancers. Tumors are not null mutant for APC - instead they accumulate truncated proteins. Many APC proteins are truncated between the second and third 20-amino acid repeats, a region known as the {beta}-catenin inhibition domain (CID), which is essential for {beta}-catenin destruction, but its mechanism of action is unclear. Here we find that cyclin dependent kinases and GSK3{beta} phosphorylate the CID region of APC in vitro. This allows the APC CID to bind to the E3 ubiquitin ligase component {beta}-TrCP1 in a phosphorylation dependent manner and this in turn regulates the rate of {beta}-catenin ubiquitylation. {beta} TrCP1 binding to the phosphorylated CID favors the retention and stabilization of the SCF {beta}-TrCP1 E3 ligase in the destruction complex and ensures that SCF {beta}-TrCP1 remains available for {beta}-catenin ubiquitylation. These findings provide a mechanism for the vital role of APCs CID region in {beta}-catenin destruction.

biochemistry↗

bioRxiv2026

Fusion Oncoprotein EWSR1::FLI1 Invades Nucleosomes at Consensus ETS Motifs and GGAA Microsatellites

Ewing sarcoma is an aggressive bone malignancy occurring in children, adolescents, and young adults. Most cases are caused by expression of the fusion oncoprotein EWSR1::FLI1, which contains the low complexity domain (LCD) of EWSR1 and the DNA-binding domain (DBD) of FLI1. Previous genomic studies indicate EWSR1::FLI1 accesses GGAA microsatellites in chromatin to function as a potent transcriptional regulator. Due to the technical challenges of purifying full-length EWSR1::FLI1, mechanistic studies biochemically characterizing its pioneer activities have been lacking. Here, we purified both full-length EWSR1::FLI1 and truncated DBD constructs to conduct biochemical and fluorescence-based experiments investigating interactions with different motifs in free DNA and nucleosomes. Both truncated and full-length EWSR1::FLI1 show efficient target binding in nucleosomes, and that the fourth alpha-helix in the FLI1 DBD enhances nucleosome-binding efficiency. Surprisingly, we also observe differences in both free DNA binding affinity and sequence preference between truncated and full-length proteins, though these changes are not apparent in nucleosome-binding assays. These findings reveal that EWSR1::FLI1 possesses a key pioneer factor property, efficiently targeting its binding site within nucleosomes, and that full-length EWSR1::FLI1 binding shifts to preferentially target GGAA repeats, even on motifs that bind a single EWSR1::FLI1 protein.

biochemistry↗